Marina Arantes Radicchi, Gabriel Ribeiro Farias, Victor Carlos Mello da Silva, Victória Paz Machado, Danielle Galdino de Souza, João Paulo Figueiró Longo, Sônia Nair Báo
{"title":"多柔比星固体脂质纳米颗粒可预防化疗相关骨质流失。","authors":"Marina Arantes Radicchi, Gabriel Ribeiro Farias, Victor Carlos Mello da Silva, Victória Paz Machado, Danielle Galdino de Souza, João Paulo Figueiró Longo, Sônia Nair Báo","doi":"10.1080/17435889.2024.2382083","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Breast cancer and its metastases involve high mortality even with advances in chemotherapy. Solid lipid nanoparticles provide a platform for drug delivery, reducing side effects and treatment-induced bone loss. A solid nanoparticle containing doxorubicin was evaluated for its ability to prevent bone loss in a pre-clinical breast cancer model. <b>Methods:</b> We investigated the effects of SLNDox in an aggressive metastatic stage IV breast cancer model, which has some important features that are interesting for bone loss investigation. This study evaluates bone loss prevention potential from solid lipid nanoparticles containing doxorubicin breast cancer treatment, an evaluation of the attenuation of morphological changes in bone tissue caused by the treatment and the disease and an assessment of bone loss imaging using computed tomography and electron microscopy. <b>Results:</b> Chemotherapy-induced bone loss was also observed in tumor-free animals; a solid lipid nanoparticle containing doxorubicin prevented damage to the growth plate and to compact and cancellous bones in the femur of tumor-bearing and healthy animals. <b>Conclusion:</b> The association of solid lipid nanoparticles with chemotherapeutic drugs with proven efficacy promotes the prevention of serious consequences of chemotherapy, reducing tumor progression, increasing quality of life and improving prognosis and survival.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevention of chemotherapy-related bone loss with doxorubicin-loaded solid lipid nanoparticles.\",\"authors\":\"Marina Arantes Radicchi, Gabriel Ribeiro Farias, Victor Carlos Mello da Silva, Victória Paz Machado, Danielle Galdino de Souza, João Paulo Figueiró Longo, Sônia Nair Báo\",\"doi\":\"10.1080/17435889.2024.2382083\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Breast cancer and its metastases involve high mortality even with advances in chemotherapy. Solid lipid nanoparticles provide a platform for drug delivery, reducing side effects and treatment-induced bone loss. A solid nanoparticle containing doxorubicin was evaluated for its ability to prevent bone loss in a pre-clinical breast cancer model. <b>Methods:</b> We investigated the effects of SLNDox in an aggressive metastatic stage IV breast cancer model, which has some important features that are interesting for bone loss investigation. This study evaluates bone loss prevention potential from solid lipid nanoparticles containing doxorubicin breast cancer treatment, an evaluation of the attenuation of morphological changes in bone tissue caused by the treatment and the disease and an assessment of bone loss imaging using computed tomography and electron microscopy. <b>Results:</b> Chemotherapy-induced bone loss was also observed in tumor-free animals; a solid lipid nanoparticle containing doxorubicin prevented damage to the growth plate and to compact and cancellous bones in the femur of tumor-bearing and healthy animals. <b>Conclusion:</b> The association of solid lipid nanoparticles with chemotherapeutic drugs with proven efficacy promotes the prevention of serious consequences of chemotherapy, reducing tumor progression, increasing quality of life and improving prognosis and survival.</p>\",\"PeriodicalId\":74240,\"journal\":{\"name\":\"Nanomedicine (London, England)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine (London, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17435889.2024.2382083\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2382083","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:即使化疗技术不断进步,乳腺癌及其转移灶的死亡率仍然很高。固体脂质纳米粒子提供了一个给药平台,可减少副作用和治疗引起的骨质流失。我们评估了一种含有多柔比星的固体纳米粒子在临床前乳腺癌模型中防止骨质流失的能力。方法:我们研究了 SLNDox 在侵袭性转移性 IV 期乳腺癌模型中的效果,该模型具有一些重要特征,对骨质流失研究很有意义。本研究评估了含有多柔比星的固体脂质纳米颗粒在乳腺癌治疗中预防骨质流失的潜力,评估了由治疗和疾病引起的骨组织形态学变化的衰减,并使用计算机断层扫描和电子显微镜评估了骨质流失成像。结果显示在无肿瘤的动物身上也观察到了化疗引起的骨质流失;含有多柔比星的固体脂质纳米粒子可防止肿瘤动物和健康动物股骨生长板以及紧密骨和松质骨的损伤。结论固体脂质纳米颗粒与疗效确切的化疗药物结合使用,可预防化疗的严重后果,减少肿瘤进展,提高生活质量,改善预后和生存率。
Prevention of chemotherapy-related bone loss with doxorubicin-loaded solid lipid nanoparticles.
Aim: Breast cancer and its metastases involve high mortality even with advances in chemotherapy. Solid lipid nanoparticles provide a platform for drug delivery, reducing side effects and treatment-induced bone loss. A solid nanoparticle containing doxorubicin was evaluated for its ability to prevent bone loss in a pre-clinical breast cancer model. Methods: We investigated the effects of SLNDox in an aggressive metastatic stage IV breast cancer model, which has some important features that are interesting for bone loss investigation. This study evaluates bone loss prevention potential from solid lipid nanoparticles containing doxorubicin breast cancer treatment, an evaluation of the attenuation of morphological changes in bone tissue caused by the treatment and the disease and an assessment of bone loss imaging using computed tomography and electron microscopy. Results: Chemotherapy-induced bone loss was also observed in tumor-free animals; a solid lipid nanoparticle containing doxorubicin prevented damage to the growth plate and to compact and cancellous bones in the femur of tumor-bearing and healthy animals. Conclusion: The association of solid lipid nanoparticles with chemotherapeutic drugs with proven efficacy promotes the prevention of serious consequences of chemotherapy, reducing tumor progression, increasing quality of life and improving prognosis and survival.